This is unpublished

Brian G.

he, him, his
Physician & Research Faculty
Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Center
Associate Professor, Division of Hematology and Oncology, University of Washington
Sites of Practice
Fred Hutchinson Cancer Center - South Lake Union

Photo: Fred Hutch

Education, Training, Board Certifications 

  • M.D., University of Chicago 
  • Residency, Hospital of the University of Pennsylvania 
  • Fellowship in Medical Oncology, UW/Fred Hutch 
  • Medical Oncology, American Board of Internal Medicine 

Clinical Expertise 

  • Immunotherapy 
  • CAR T-cell therapy 
  • Hematopoietic stem cell transplantation 
  • Lymphoma



Research and/or clinical interests 

Dr. Brian Till develops new treatments for lymphoma by genetically engineering a patient's own T cells so they can more effectively attack cancer. T cells target and kill cancer cells by binding to specific proteins on the tumor cells with molecules called T-cell receptors. Dr. Till's research involves making synthetic receptors known as chimeric antigen receptors, or CARs, that home in on lymphoma cells. He led the first published trial testing CAR T cells as a treatment for lymphoma patients. Dr. Till continues to carry out a variety of immunological, genetic and gene-expression studies in the clinic to understand why CAR T-cell therapies work for some patients and fail for others. This research will help improve the next iterations of this experimental therapy.